Adverse Drug Reaction Classification System

         

Pharmaceutical Information
Drug Name Moxifloxacin hydrochloride
Drug ID BADD_D01502
Description Moxifloxacin is a synthetic fluoroquinolone antibiotic agent. Bayer AG developed the drug (initially called BAY 12-8039) and it is marketed worldwide (as the hydrochloride) under the brand name Avelox (in some countries also Avalox) for oral treatment.
Indications and Usage For the treatment of sinus and lung infections such as sinusitis, pneumonia, and secondary infections in chronic bronchitis. Also for the treatment of bacterial conjunctivitis (pinkeye).
Marketing Status approved; investigational
ATC Code J01MA14; S01AE07
DrugBank ID DB00218
KEGG ID D00874
MeSH ID D000077266
PubChem ID 101526
TTD Drug ID D0ZV0Z
NDC Product Code 48943-0025; 55111-064; 58032-0131; 40032-034; 60429-893; 50370-0001; 51927-4833; 51991-943; 72789-037; 29967-0005; 49574-522; 63323-850; 65862-627; 0093-7387; 50090-4100; 70518-3738; 51927-0167; 0781-7135; 49587-106; 50090-4058; 66298-8507; 67296-1616; 67457-323; 72789-038; 13668-201; 0078-0939; 65862-603; 68084-722; 0832-1410; 50268-576; 51927-0089; 57237-156
UNII C53598599T
Synonyms Moxifloxacin | 1-Cyclopropyl--7-(2,8-diazabicyclo(4.3.0)non-8-yl)-6-fluoro-8-methoxy-1,4-dihydro-4-oxo-3-quinolinecarboxylic acid | Octegra | Proflox | Moxifloxacin Hydrochloride | Avelox | Avalox | Izilox | Actira | BAY 12-8039 | BAY 12 8039 | BAY-12-8039 | BAY 128039 | BAY-128039 | BAY128039
Chemical Information
Molecular Formula C21H25ClFN3O4
CAS Registry Number 186826-86-8
SMILES COC1=C2C(=CC(=C1N3CC4CCCNC4C3)F)C(=O)C(=CN2C5CC5)C(=O)O.Cl
Chemical Structure
ADRs Induced by Drug
*The priority for ADR severity classification is based on FAERS assessment, followed by the most severe level in CTCAE rating. If neither is available, it will be displayed as 'Not available'.
**The 'Not Available' level is hidden by default and can be restored by clicking on the legend twice..
ADR Term ADReCS ID ADR Frequency (FAERS) ADR Severity Grade (FAERS) ADR Severity Grade (CTCAE)
Eosinophil count increased13.01.06.004--Not Available
Eosinophilia01.02.04.001--
Epistaxis24.07.01.005; 22.04.03.001--
Eructation07.01.02.003--
Erythema23.03.06.001--Not Available
Erythema multiforme23.03.01.003; 10.01.03.015--
Euphoric mood19.04.02.006--
Eye disorder06.08.03.001--Not Available
Eye irritation06.04.05.003--Not Available
Eye pain06.08.03.002--
Eyelid oedema23.04.01.003; 10.01.05.001; 06.04.04.004--Not Available
Face oedema23.04.01.004; 10.01.05.002; 08.01.07.003--
Facial pain08.01.08.012--
Fatigue08.01.01.002--
Feeling abnormal08.01.09.014--Not Available
Flatulence07.01.04.002--
Fungal infection11.03.05.001--Not Available
Fungal skin infection23.11.03.006; 11.03.05.002--Not Available
Gait disturbance15.03.05.013; 17.02.05.016; 08.01.02.002--
Galactorrhoea21.05.02.002; 05.03.04.002--Not Available
Gamma-glutamyltransferase increased13.03.04.024--
Gastritis07.08.02.001--
Gastrooesophageal reflux disease07.02.02.003--
Gastroenteritis11.01.07.004; 07.19.03.001--Not Available
Gastrointestinal candidiasis07.19.02.003; 11.03.03.011--Not Available
Gastrointestinal disorder07.11.01.001--Not Available
Gastrointestinal haemorrhage24.07.02.009; 07.12.02.001--Not Available
Gastrointestinal pain07.01.05.005--
Generalised tonic-clonic seizure17.12.01.002--Not Available
Gingivitis11.01.04.013; 07.09.10.002--
The 5th Page    First    Pre   5 6 7 8 9    Next   Last    Total 14 Pages